KalVista Pharmaceuticals (KALV) Cash & Current Investments (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Cash & Current Investments data on file, last reported at $191.5 million in Q3 2025.

• For the quarter ending Q3 2025, Cash & Current Investments rose 9.87% year-over-year to $191.5 million; the trailing twelve-month figure through Jul 2025 stood at $191.5 million (up 9.87% YoY), and the FY2025 full-year result was $220.6 million, up 4.86% from the prior year.
• Cash & Current Investments fell to $191.5 million in Q3 2025, from $220.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $268.3 million in Q4 2024 to a low of $50.3 million in Q1 2021.
• A 5-year average of $167.8 million and a median of $171.7 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments surged 287.17% in 2022 and slumped 55.97% in 2024, its largest moves.
• Tracing KALV's Cash & Current Investments over 5 years: stood at $209.8 million in 2021, then plunged by 41.72% to $122.3 million in 2022, then decreased by 15.62% to $103.2 million in 2023, then jumped by 160.09% to $268.3 million in 2024, then slipped by 28.65% to $191.5 million in 2025.
• Business Quant data shows KALV's Cash & Current Investments at $191.5 million in Q3 2025, $220.6 million in Q2 2025, and $268.3 million in Q4 2024.